Yahoo Finance Today's Research Reports on Canopy Growth, Aphria, Aurora Cannabis and MedReleaf
NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI Initiates Coverage on:
Canopy Growth Corp.
https://ub.rdinvesting.com/news/?ticker=WEED-TO
Aphria Inc.
https://ub.rdinvesting.com/news/?ticker=APH-TO
Aurora Cannabis Inc.
https://ub.rdinvesting.com/news/?ticker=ACB-V
MedReleaf Corp.
https://ub.rdinvesting.com/news/?ticker=LEAF-TO
Canopy Growth's stock moved 1.75% lower Friday, to close the day at $8.41. The stock recorded a trading volume of 1,253,630 shares, which was below its three months average volume of 2,136,330 shares. In the last year Canopy Growth Corporation's shares have traded in a range of 2.61 - 17.86. The share price has gained 222.22% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $7.98 is below its 200-day moving average of $9.82. Shares of Canopy Growth have fallen approximately 7.99 percent year-to-date.
Access RDI's Canopy Growth Research Report at:
https://ub.rdinvesting.com/news/?ticker=WEED-TO
On Friday, shares in Aphria recorded a trading volume of 824,572 shares, which was below the three months average volume of 1,806,880 shares. The stock ended the day 2.83% lower at 5.49. The share price has gained 273.47% from its 52 week low with a 52 week trading range of 1.47 - 8.77.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $5.61 is below its 200-day moving average of $5.91. Shares of Aphria are trading at a Price to Earnings ratio of 60.33. Shares of Aphria have fallen approximately 12.16 percent year-to-date.
Access RDI's Aphria Research Report at:
https://ub.rdinvesting.com/news/?ticker=APH-TO
Aurora Cannabis' stock moved 1.37% lower Friday, to close the day at $2.16. The stock recorded a trading volume of 655,468 shares, which was below its three months average volume of 3,029,360 shares. In the last year Aurora Cannabis' shares have traded in a range of 1.56 - 3.95. The share price has gained 38.46% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $2.39 is below its 200-day moving average of $2.46. Shares of Aurora Cannabis have fallen approximately 6.09 percent year-to-date.
Access RDI's Aurora Cannabis Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACB-V
On Friday, shares in MedReleaf recorded a trading volume of 53,350 shares, which was below the three months average volume of 241,688 shares. The stock ended the day 1.49% higher at 8.53. The share price has gained 25.18% from its 52 week low with a 52 week trading range of 6.81 - 9.65.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $8.96 is at its 200-day moving average of $8.96. Shares of MedReleaf have gained approximately 15.2 percent year-to-date.
Access RDI's MedReleaf Research Report at:
https://ub.rdinvesting.com/news/?ticker=LEAF-TO
Our Actionable Research on Canopy Growth Corp. (TSX:WEED), Aphria Inc. (TSX:APH), Aurora Cannabis Inc. (TSX.V: ACB) and MedReleaf Corp. (TSX:LEAF) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
